What are brokers saying about the CSL share price in May?
Image source: Getty Images
The CSL Limited (ASX: CSL) share price is having a decent year so far.
Since the start of 2023, the biotherapeutics giant’s shares have risen almost 5% to close at $301.27 on Monday.
This compares favourably to the ASX 200 index and its 3.4% gain.
The big question now, though, is can the CSL share price keep rising?
In order to answer this question, let’s take a look at what brokers are saying about the company’s shares.
Can the CSL share price keep rising?
Well, I have good news for you. All the major brokers believe the CSL share price has room to climb from current levels.
Here’s a summary in alphabetical order:
The team at Citi currently has a buy rating and $350 price target on the company’s shares. This implies potential upside of over 16% for investors over the next 12 months. Incidentally, this is the highest price target that I have seen.
Goldman Sachs is sitting on the fence at the moment with its neutral rating and $314.00 price target. This suggests the CSL share price could rise a little over 4% from here. Not great, but a gain is a gain.
Moving on, Macquarie is a fan and currently has an outperform rating and $344.00 price target on its shares. If it reached this level, it would mean a gain of just over 14%.
Analysts at Morgan Stanley are also positive on CSL. They currently have an overweight rating and $339.00 price target, which implies potential upside of 12.5% for investors.
Finally, Morgans is another broker that is bullish on the company. It currently has an add rating and $337.92 price target on its shares. This would mean a 12% gain if the CSL share price climbed to this level.
All in all, it seems that now is a good time to be a shareholder of this biotherapeutics leader if brokers are on the money with their recommendations.